AVDL - Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q1 2022 Results - Earnings Call Transcript

Avadel Pharmaceuticals plc (AVDL) Q1 2022 Earnings Conference Call May 9, 2022 08:30 ET Company Participants Brandi Robinson - Senior Vice President of Corporate Affairs Douglas Williamson - Chief Medical Officer Gregory Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical & Clinical Affairs Richard Kim - Chief Commercial Officer Tom McHugh - Senior Vice President & Chief Financial Officer Conference Call Participants Francois Brisebois - Oppenheimer Marc Goodman - SVB Securities Oren Livnat - H.C. Wainwright Matt Kaplan - Laddenburg Robin Garner - Craig Hallum Adam Evertts - LifeSci Capital Presentation Operator Ladies and gentlemen, thank you for standing by and welcome to the Avadel Pharmaceuticals' First Quarter 2022 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded. [Operator Instructions] I would now like to hand the conference over to your speaker, Ms. Brandi Robinson, Senior Vice President of Corporate Affairs. Please

For further details see:

Avadel Pharmaceuticals plc (AVDL) CEO Gregory Divis on Q1 2022 Results - Earnings Call Transcript